AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02111720 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maybe, Maybe Not
Description: The goals of session one are to introduce participants to the intervention, to assess current decision context, to assist in the clarification of participant values, and to encourage the participant to set specific goals for disclosure decision-making. The goals for session two are to explore the participants' motivations to disclose or not to disclose and the potential costs and rewards of both disclosing and not disclosing. The goals for session three are to guide participants through disclosure decision making, and to support comfort/acceptance with decisions made. The goal of session four is to support the decision-making process. The booster session is used to reinforce the effects of the intervention through continued discussion of disclosure decisions in the preceding months, strategies used in disclosing, and rewards and costs of decision-making.
Study NCT02111720 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comprehensive Risk Counseling and Services
Description: CRCS combines traditional case management and HIV risk-reduction in an individualized, client-centered program which focuses on the reduction of risk behavior and addresses a client's psychosocial and medical needs.CRCS focuses on seven core elements: recruitment and engagement; screening, enrolling, and assessing; prevention planning; risk reduction counseling; referrals and service coordination; monitoring; and discharge and maintenance. These core elements represent the framework of the intervention, and provide enough flexibility to allow implementation that most appropriately serves the needs of clients.
Study NCT02651519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.25% ropivacaine hydrochloride
Description: stellate-ganglion block with 0.25% ropivacaine hydrochloride
Study NCT02651519 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: saline
Description: stellate-ganglion block with saline
Study NCT01179737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Nilotinib capsules for oral administration at 50 mg, 150 mg twice a day and 300 mg (2 capsules of 150 mg) twice a day.
Study NCT01179737 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to nilotinib
Description: Placebo to nilotinib capsules for oral administration to match 50 mg, 150 mg and 300 mg capsules twice a day
Study NCT03235115 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Methafilcon A IV
Description: Contact Lens
Study NCT03235115 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ocufilcon B
Description: Contact Lens
Study NCT03235115 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Omafilcon A
Description: Contact Lens
Study NCT00299559 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: smart textiles containing menthol, camphor, cineol
Description: application to skin
Study NCT03667417 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: standardized data collection and 10-year prospective follow-up
Study NCT00947024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg Glipizide Tablet (Geneva Pharmaceutical, Inc.), Administered Immediately After a Standard Breakfast.
Study NCT00947024 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10 mg Glucotrol Tablet (Roerig), Administered Immediately After a Standard Breakfast.
Study NCT00947024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg Glipizide Tablet (Geneva Pharmaceutical, Inc.), Administered After an Overnight Fast.
Study NCT00436098 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motorpedagogic exercise
Description: physical training
Study NCT03600012 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cycling Functional Electrical Stimulation
Study NCT03600012 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Study NCT03600012 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Study NCT00329641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT00329641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV
Study NCT00329641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given orally
Study NCT04927871 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Total Diet Replacement (TDR)
Description: The nutritionist will provide a total diet replacement (TDR) with Low-Energy Liquid-Diet (LELD - 811 kcal/day, 64 g protein, 132 g carbohydrate, 6 g fat) and the food reintroduction for two months.
Study NCT04927871 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medical Nutritional Therapy (MNT)
Description: The nutritionist will provide Medical Nutritional Therapy (MNT) using the transcultural Diabetes Nutritional Algorithm (tDNA) Toolkit adapted for Venezuela for four months.
Study NCT04927871 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Prevention Program 4 months
Description: The coach will provide a group-based Diabetes Prevention Program (DPP) version in weekly encounters during 4-months.
Study NCT04927871 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes Prevention Program
Description: The coach will provide a group-based Diabetes Prevention Program (DPP) version in weekly encounters during 6-months.
Study NCT00668785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: Ranibizumab 0.5mg at baseline and then again at 30 days and/or 60 days after PRP as deemed appropriate by the Investigator.
Study NCT04159805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-079
Description: TAK-079 subcutaneous injection
Study NCT04159805 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-079 Placebo
Description: TAK-079 placebo-matching subcutaneous injection
Study NCT02930837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alteplase
Study NCT03124121 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Golimumab
Description: A biologic agent which acts by antagonising the effects of tumour necrosis factor (TNF) alpha
Study NCT02656563 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radium 223 Dichloride (Xofigo®)
Description: Radium 223 Dichloride (Xofigo®) monthly for six months
Study NCT02841566 — intervention group
Intervention type: OTHER
Intervention: questionnaire
Study NCT02086825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: (Xifaxin®, Salix Pharmaceuticals) 550mg tablet twice daily.
Study NCT02086825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactulose
Description: 20g dose titrated
Study NCT00405743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-4055
Description: CP-4055 Continuous IV infusion
Study NCT00405743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-4055
Description: CP4055 2 and 4 hour IV infusion
Study NCT00771329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB023
Description: Single IV doses of BIIB023 in dose-escalating cohorts
Study NCT00771329 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (sterile normal saline)
Description: Single IV dose of Placebo
Study NCT01251887 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Linoleic Acid
Study NCT01251887 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic Acid
Study NCT01251887 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic Acid
Study NCT01831726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dovitinib (TKI258)
Description: Dovitinib (TKI) will be dosed on a flat scale of 500 mg on a 5 days on/2 days off dosing schedule.
Study NCT04168996 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualized discharge planning
Description: Discharge planning is designed to ensure healthcare continuity, avoid preventable poor outcomes among at-risk populations, and promote the safe and timely transfer of patient care. The individualized discharge planning is characterized to take into account the preferences, interests and clinical profile of each patient.
Study NCT04823117 — intervention group
Intervention type: OTHER
Intervention: music therapy
Description: music includes nature sounds recommended by the Turkish Psychological Association
Study NCT00915785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 azacytidine
Description: Patients will receive azacytidine 75 mg/m2/day SC for 7 days every 28 days for up to 6 cycles, unless they are discontinued from the treatment.
Study NCT04035863 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low level laser therapy
Description: For the PBM protocol, articles of interest were identified through analyses of titles and abstracts. Articles addressing PBM in experimental models or clinical trials of spinal cord injuries were included and articles not pertinent to the proposed study were excluded. Next, the selected articles were analyzed and used for the creation of an initial protocol (Table 1).~For irradiation, the individuals will be positioned comfortably in lateral decubitus on the examining table. Three points will be irradiated above the lesion level, which will be located using an imaging exam brought by the guardian on the day of the evaluation. After determining the lesion level, palpation of the transverse processes of the vertebrae will be performed. The same laser device (Laser DMC Therapy EC) will be used for both groups. For the placebo group, the device will emit sound but not light.
Study NCT04035863 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Low level laser therapy
Description: For the PBM protocol, articles of interest were identified through analyses of titles and abstracts. Articles addressing PBM in experimental models or clinical trials of spinal cord injuries were included and articles not pertinent to the proposed study were excluded. Next, the selected articles were analyzed and used for the creation of an initial protocol (Table 1).~For irradiation, the individuals will be positioned comfortably in lateral decubitus on the examining table. Three points will be irradiated above the lesion level, which will be located using an imaging exam brought by the guardian on the day of the evaluation. After determining the lesion level, palpation of the transverse processes of the vertebrae will be performed. The same laser device (Laser DMC Therapy EC) will be used for both groups. For the placebo group, the device will emit sound but not light.
Study NCT04167085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Doxycycline, 100 mg twice a day for 2 months
Study NCT04167085 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo, twice a day for 2 months
Study NCT02618785 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hysterosalpingography
Description: Starting procedure by using largest appropriate speculum for maximum cervical exposure. Cleanse the cervix with povidone iodine. A tenaculum was applied to the anterior cervix to help for stabilization and counter-traction. Then insert a sterile Rubin's cannula into the cervix uteri. A scout radiograph of the pelvis was obtained with the catheter in place before contrast material was instilled. After that the water soluble contrast media was slowly instilled through the cannula appropriate volume range 10-15 ml., with fluoroscopic images obtained intermittently to evaluate the uterus, fallopian tubes and tubal patency
Study NCT02618785 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: hysterosalpingography
Description: Starting procedure by using largest appropriate speculum for maximum cervical exposure. Cleanse the cervix with povidone iodine. A tenaculum was applied to the anterior cervix to help for stabilization and counter-traction. Then insert a sterile Rubin's cannula into the cervix uteri. A scout radiograph of the pelvis was obtained with the catheter in place before contrast material was instilled. After that the water soluble contrast media was slowly instilled through the cannula appropriate volume range 10-15 ml., with fluoroscopic images obtained intermittently to evaluate the uterus, fallopian tubes and tubal patency
Study NCT04236245 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Venclose RF System
Description: Treatment of great saphenous vein (GSV) using Venclose RF System
Study NCT01890499 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low Residue diet arm.
Description: Interventional arm is to provide low residue diet on postoperative day one.
Study NCT01890499 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low Residue diet arm.
Description: Interventional arm is to provide low residue diet on postoperative day one.
Study NCT04177732 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Collection of sulcular (crevicular) fluid
Description: Sterile paper strips will be used for collecting crevicular fluid
Study NCT04177732 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Probing depth
Description: Williams SE manual probe will be used to measure the probing depth
Study NCT04177732 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Bleeding on probing
Description: Williams SE manual probe will be used to probe the sulcus a oserve the gingival reaction
Study NCT04177732 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Gingival index
Description: Modified Löe and Silness criteria will be used for evaluating the gingival index score
Study NCT04177732 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Bone loss rate of alveolar bone
Description: Using modification of criteria described by Schei et al, bone loss rate of alveolar bone will be analyzed on radiographic assessment
Study NCT00654615 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intramedullary Radius Fixation (Micronail)
Description: After adequate anesthesia was obtained and the patient was prepared for surgery, distraction was applied to the fracture site and preliminary reduction of the distal radius fracture was performed under fluoroscopic guidance. A pin was inserted to maintain the fracture reduction, then the Micronail was inserted inside the radius. The metaphyseal defect created by the fracture was filled using allograft or autograft bone material. Limited incisions at either the radial or ulnar columns was performed to achieve acceptable reduction of the fracture. Radiographic parameters were used to evaluate the results of the surgical management with intramedullary nailing.
Study NCT00654615 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Volar Plate Fixation
Description: After adequate anesthesia, longitudinal traction of the wrist was applied. Based on the fracture pattern, fragments were reduced and stabilized using either one 2.4mm titanium pre-contoured locking plate or a combination of locking plates. Arthrotomy was performed to verify that the fracture fragments were reduced. Plates were contoured to fit boney contours as needed. Allograft or autograft was placed in the fracture repair site as necessary. Radiographic landmarks were evaluated. Care was taken to ensure that plates were covered with periosteum or retinaculum to reduce the incidence of possible soft tissue irritation caused by the plate on the bone. The skin incision was closed; a removable splint applied.
Study NCT02367742 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Endurance Activity (EA)
Description: Subjects have followed a program of endurance activity consisting in a 30 minute walk, 5 times/week. Exercise intensity started from the 60% of the maximum heart rate and raised up to the 75%.
Study NCT02367742 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: EA + Resistance Training (RT)
Description: Subjects have followed a program combining endurance activity (EA) and resistance training (RT) consisting in a 60 minute work session, 3 times/week consisting in:~* Walk (30 minutes): exercise intensity started from the 60% of the maximum heart rate and raised up to the 75%.~* Musculation (30 minutes): training of the bigger muscle groups (chest, shoulders, arms, abdomen, back, glutei and legs). Exercise intensity started from the 65% of the maximum rated load and raised up to the 75%.
Study NCT02013856 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low Epicatechin and procyanidin
Description: 70 mg epicatechin and 65 mg procyanidins once daily for 28 days
Study NCT02013856 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Epicatechin and procyanidin
Description: 140 mg epicatechin and 130 mg procyanidins once daily for 28 days
Study NCT02013856 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High procyanidin
Description: No epicatechin and 130 mg procyanidins once daily for 28 days
Study NCT02013856 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control once daily for 28 days
Study NCT01738841 — intervention group
Intervention type: BIOLOGICAL
Intervention: Priorix-Tetra™
Description: Single dose, subcutaneous injection
Study NCT01738841 — intervention group
Intervention type: OTHER
Intervention: Safety data collection
Description: Recording of adverse events, using diary cards
Study NCT02739308 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive Training
Description: In this study the training program will be developed for 12 weeks and will be applied during the heating of the athletes , three times a week and the duration of each session is 30 minutes. Each week will be chosen three of the 14 exercises adapted for fencing athletes , and preferably one of each category.
Study NCT02739308 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: The control group will not make the intervention and will continue with usual training fencing.
Study NCT04909268 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: HIV testing
Description: serology for HIV testing
Study NCT00842075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pramlintide
Description: subcutaneous injection (15 mcg initial dose)prior to meals
Study NCT02290600 — intervention group
Intervention type: DEVICE
Intervention: Continuous Glucose Monitor
Description: CGM sensor calibration individualization
Study NCT02156375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Participants will receive a single 6 milligram per kilogram (mg/kg) intravenous infusion of 90 milligram per milliliter (mg/mL) liquid in vial (LIV) formulation, diluted in saline, on Day 1.
Study NCT02156375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Participants will receive a single 6 mg/kg intravenous infusion of 5 mg/mL LIV formulation, diluted in saline, on Day 1.
Study NCT00829816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimebon
Study NCT00829816 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02634372 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMDR therapy
Description: EMDR: We designed a specific EMDR Bipolar Protocol which consists of a detailed interview with respect to traumatic events, the treatment of those with the EMDR standard protocol, and five new specific bipolar adapted EMDR protocols focusing on adherence, insight, de-idealisation of manic symptoms, prodromal symptoms and moodstabilization.
Study NCT02634372 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Therapy
Description: Supportive therapy: Therapists adopt a client-centred focus, meaning that whatever problems the patient presents will be dealt with by providing emotional support and general advise. If no specific topic is mentioned by the patient, information about bipolar disorder and medication will be delivered by the therapist without referring to written or any other material.
Study NCT01827215 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Patient Advocate (VPA)
Description: Intervention participants will have access to the Virtual Patient Advocate (VPA) system for a period of 12 months. They will be encouraged to log on every two weeks or twice a month, but frequency and duration of conversations with the VPA is at the discretion of the participant.
Study NCT02013570 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: 2µg/kg dexmedetomidine in 2 ml normal saline (1 ml per tonsil),
Study NCT02013570 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexmedetomidine
Description: 2µg/kg dexmedetomidine in 2 ml normal saline (1 ml per tonsil),
Study NCT00259974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab
Study NCT03906721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sugar pill used to condition patients.
Study NCT03906721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: An opioid used for analgesia.
Study NCT03906721 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Oxycodone
Description: An opioid used for analgesia.
Study NCT03906721 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Essential Oil
Description: An aromatic oil used for conditioning.